Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea
- Author:
Myeung-su LEE
1
;
Chang Hoon LEE
;
Hye Soon LEE
;
Yoon-Kyoung SUNG
;
Jung Ran CHOI
;
Kyungsu PARK
;
Mi-Kyoung LIM
;
Byoong Yong CHOI
;
Hyoun-Ah KIM
;
Seung Won CHOI
;
Yusun LEE
;
Wan-Hee YOO
Author Information
- Publication Type:Original Article
- From:Journal of Rheumatic Diseases 2021;28(2):68-75
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disorder that impairs patients’ overall health-related quality of life (HRQOL). In this study, we evaluated the effect of adalimumab in Korean patients with active RA on HRQOL.
Methods:Patients included in the study had moderate to severe active RA that did not respond to conventional drugs with a Disease Activity Score of 28 joints ＞3.2 and were biologics-naïve. All patients received adalimumab 40 mg subcutaneously every other week and were followed for 24 weeks. The primary endpoint was the change in baseline Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 24. Secondary endpoints were changes in the EuroQol 5-dimension 3-Level (EQ-5D-3L) baseline score and Short Form 36-Item Health Survey (SF-36) domain scores at weeks 12 and 24 and change in baseline HAQ-DI score at week 12.
Results:In total, 91 Korean patients were included. Ninety-three percent of patients were in high disease activity with a baseline mean DAS28 value of 6.1 within all patients. The mean change from baseline in HAQ-DI scores were −0.46 at week 12 and∼0.67 at week 24 (p＜0.0001). Additionally, EQ-5D-3L score at weeks 12 and 24 had significantly improved (p＜0.0001) compared to baseline. SF-36 at weeks 12 and 24 had significantly improved (p＜0.0001, p=0.0001) compared to baseline.
Conclusion:Treatment with adalimumab resulted in significant improvement in HAQ-DI, EQ-5D-3L, and SF-36 scores at 12 and 24 weeks in Korean RA patient.
